Nuvectis Pharma, Inc. (NVCT) earnings
NVCT earnings moved a median of -3.71% by the close. Quarterly and annual NVCT reports and results, each read against the price at its own news timestamp. Back to the NVCT overview →
22 measured NVCT earnings events.
Where these NVCT earnings landedvs 22 measured NVCT earnings reactions
| Middle 50% of NVCT earnings reactions | -5.60% to +3.07% |
|---|---|
| Median reaction (to close) | -3.71% |
| Measured reactions | 22 |
Point-in-time · zero look-ahead
Half of the 22 NVCT earnings events with a measured close landed between -5.60% and +3.07%; 27% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Nuvectis Pharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | -3.22% | +4.36% | |
| Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights | Press release | -3.22% | +4.36% | |
| Form 10-Q Nuvectis Pharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.79% | +9.35% | |
| Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights | Press release | +0.79% | +9.35% | |
| Form 10-K Nuvectis Pharma, Inc. For: Dec 31 | SEC filing · Form 10-K | -1.13% | -0.79% | |
| CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights | Press release | -2.33% | -5.31% | |
| Form 10-Q Nuvectis Pharma, Inc. For: Sep 30 | SEC filing · Form 10-Q | -2.33% | -5.31% | |
| Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights | Press release | -2.33% | -5.31% | |
| Form 10-Q Nuvectis Pharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.28% | -3.63% | |
| Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights | Press release | +0.28% | -3.63% | |
| Form 10-Q Nuvectis Pharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | +4.21% | -2.88% | |
| Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights | Press release | +0.15% | -6.67% | |
| Form 10-K Nuvectis Pharma, Inc. For: Dec 31 | SEC filing · Form 10-K | +3.23% | -3.79% | |
| Form 10-Q Nuvectis Pharma, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.48% | +19.45% | |
| Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights | Press release | +0.48% | +19.45% | |
| Form 10-Q Nuvectis Pharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.00% | -5.70% | |
| Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights | Press release | +0.00% | -5.70% | |
| Form 10-Q Nuvectis Pharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.00% | -8.14% | |
| Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights | Press release | +1.20% | -4.39% | |
| Form 10-K Nuvectis Pharma, Inc. For: Dec 31 | SEC filing · Form 10-K | -0.69% | -3.44% | |
| Form 10-Q Nuvectis Pharma, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -5.72% | |
| Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights | Press release | +0.00% | -5.72% |
Keep exploring
More NVCT: analyst actions → · SEC filings → · NVCT overview →